We are excited to welcome new Bio Nebraska member, Neurocarrus!
Neurocarrus is developing a breakthrough therapeutic biologic (N-001) to fulfill the unmet need for a product that can safely and specifically treat peripheral pain. N-001 was engineered for individuals experiencing acute and chronic pain. Unlike opioids, N-001 cannot be addictive because it cannot pass the blood-brain barrier due to its size. Neurocarrus is a university spinout founded by Paul Blum a co-inventor of the recently patented technology. The company has exclusively licensed the IP for all fields of use including the delivery of other therapeutics to sensory neurons. Since inception, the company graduated from the IndieBio incubator in San Francisco and raised several rounds of funding. In addition, it has published several high ranking articles about its technology detailing in vitro mechanisms, and in vivo pain efficacy. Recently, Neurocarrus received a Phase I SBIR from NINDS and became a participant in the NINDS PSPP program sponsored by the HEAL initiative.